HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Candid Overview Of Cosmetics Regime Signals Support For Reform Bill

This article was originally published in The Rose Sheet

Executive Summary

In a letter to California Democratic Senator Dianne Feinstein, FDA’s Acting Associate Commissioner for Legislation Dayle Cristinzio acknowledges the agency’s limited insight into cosmetic formulations and safety information, which makes it a struggle to respond to issues as they arise. Feinstein characterizes the letter as an admission of current system failings and a nod of support for her Personal Care Products Safety Act.

You may also be interested in...

Former FDA Cosmetics Director Weighs In On Senator Hatch's Draft FCSMA

Under the draft FDA Cosmetic Safety and Modernization Act, a product could be deemed adulterated "regardless of whether it is known which particular substance or substances may render the cosmetic injurious." EAS Consulting Group's John Bailey offers his perspective on the provision and the overall bill in an exchange with the Rose Sheet.

Think FDA Inspections Are Painful Now? These Could Be The Good Old Days

ICMAD's recent regulatory workshop offered perspective from FDA's Linda Katz and industry experts on the inspection process for cosmetics facilities under current law. It's clear that FDA inspections can be an ordeal, but that would pale in comparison to challenges that could arise under the proposed Personal Care Products Safety Act.

2016 In Review: FDA Transparency, Claims Enforcement A One-Off?

The Rose Sheet’s coverage of FDA’s warning letter crackdown and data sharing produced some of its most-read stories of 2016, based on online analytics. Legislative proposals and cosmetic safety issues in the US mainstream factored in the agency’s transparency work, a situation that may not repeat in the new year.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts